{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:31:57Z","timestamp":1793943117590,"version":"4.8.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.rcsop.2026.100835","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:27:16Z","timestamp":1789226836000},"page":"100835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Roles and perceived responsibilities of investigators and pharmacists in the monitoring of drug-drug interactions in clinical trials - a mixed methods study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3561-3288","authenticated-orcid":false,"given":"Anne-Ja\u00ebl","family":"Elskamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0091-7953","authenticated-orcid":false,"given":"Gijsbert","family":"Schouten-Ritskes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-2116","authenticated-orcid":false,"given":"Joris","family":"van der Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-2438","authenticated-orcid":false,"given":"Jacqueline","family":"Hugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5723-5371","authenticated-orcid":false,"given":"Niels","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rcsop.2026.100835_bb0005","article-title":"Importance of clinical trials and contributions to contemporary medicine: commentary","volume":"57","author":"Zhang","year":"2025","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.rcsop.2026.100835_bb0010","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cpt.3596","article-title":"Clinical Evidence 2030","volume":"117","author":"Arlett","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rcsop.2026.100835_bb0015","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fphar.2020.00326","article-title":"An increasing trend in the prevalence of polypharmacy in Sweden: a nationwide register-based study","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.rcsop.2026.100835_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5880","article-title":"Prevalence of polypharmacy in elderly population worldwide: a systematic review and meta-analysis","volume":"33","author":"Wang","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.rcsop.2026.100835_bb0025","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/bcp.16113","article-title":"The prevalence of polypharmacy in older Europeans: a multi-national database study of general practitioner prescribing","volume":"90","author":"Bennie","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.rcsop.2026.100835_bb0030","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","article-title":"Drug interactions in cancer therapy","volume":"6","author":"Scripture","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.rcsop.2026.100835_bb0035","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/pds.1351","article-title":"Hospitalisations and emergency department visits due to drug-drug interactions: a literature review","volume":"16","author":"Becker","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"18","key":"10.1016\/j.rcsop.2026.100835_bb0040","doi-asserted-by":"crossref","first-page":"E4304","DOI":"10.1073\/pnas.1803294115","article-title":"Deep learning improves prediction of drug-drug and drug-food interactions","volume":"115","author":"Ryu","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100835_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/14740338.2012.631910","article-title":"Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions","volume":"11","author":"Magro","year":"2012","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100835_bb0050","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12885-021-08050-w","article-title":"Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy","volume":"21","author":"Marcath","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.rcsop.2026.100835_bb0055","article-title":"Medication safety in trials is not sufficiently guaranteed","volume":"163","author":"Ferrier","year":"2019","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100835_bb0060","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1186\/s12885-018-5076-0","article-title":"Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials","volume":"18","author":"Marcath","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.rcsop.2026.100835_bb0065","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/OP.22.00281","article-title":"Impact of medication reconciliation in oncology early phase studies: a drug-drug interaction retrospective study","volume":"20","author":"Malifarge","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.rcsop.2026.100835_bb0070","unstructured":"Guidelines for Good Clinical Practices E6, (2016)."},{"key":"10.1016\/j.rcsop.2026.100835_bb0075","series-title":"Clinical Trials Regulation No. 536\/2014. OJ","author":"European Parliament and the Council","year":"2014"},{"key":"10.1016\/j.rcsop.2026.100835_bb0080","unstructured":"Dutch Medicines Act, (2024)."},{"key":"10.1016\/j.rcsop.2026.100835_bb0085","author":"KNMP"},{"key":"10.1016\/j.rcsop.2026.100835_bb0090","author":"KNMP"},{"key":"10.1016\/j.rcsop.2026.100835_bb0095","author":"Z-index"},{"key":"10.1016\/j.rcsop.2026.100835_bb0100","author":"Volg je zorg"},{"key":"10.1016\/j.rcsop.2026.100835_bb0105","author":"European Association of Hospital Pharmacists"},{"issue":"4","key":"10.1016\/j.rcsop.2026.100835_bb0110","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","article-title":"Reflecting on reflexive thematic analysis","volume":"11","author":"Braun","year":"2019","journal-title":"Qual Res Sport, Exerc Health"},{"key":"10.1016\/j.rcsop.2026.100835_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s11135-021-01182-y","article-title":"A worked example of Braun and Clarke\u2019s approach to reflexive thematic analysis","volume":"56","author":"Byrne","year":"2022","journal-title":"Qual Quant"},{"key":"10.1016\/j.rcsop.2026.100835_bb0120","author":"KNMP"},{"issue":"5","key":"10.1016\/j.rcsop.2026.100835_bb0125","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jcph.6168","article-title":"Patients in clinical trials are sub-optimally protected for drug\u2013drug interactions: a call for action","volume":"65","author":"Burger","year":"2025","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.rcsop.2026.100835_bb0130","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2146\/ajhp180038","article-title":"Pharmacists' critical role in cancer clinical trials","volume":"75","author":"Goodin","year":"2018","journal-title":"Am J Health-Syst Pharm"},{"issue":"4","key":"10.1016\/j.rcsop.2026.100835_bb0135","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00280-021-04331-0","article-title":"Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy","volume":"88","author":"Leenhardt","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.rcsop.2026.100835_bb0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.sapharm.2025.11.004","article-title":"Ensuring the quality use of medicines in clinical trials: a review and perspective on optimising the role of pharmacists","volume":"22","author":"Bajorek","year":"2026","journal-title":"Res Social Adm Pharm"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276626001332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276626001332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:23:21Z","timestamp":1793942601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276626001332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":28,"alternative-id":["S2667276626001332"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100835","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roles and perceived responsibilities of investigators and pharmacists in the monitoring of drug-drug interactions in clinical trials - a mixed methods study","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100835"}}